Literature DB >> 22075712

Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by regulating apoptosis independently of p53 status.

Lingchao Chen1, Junxia Zhang, Lei Han, Anling Zhang, Chunzhi Zhang, Yongri Zheng, Tao Jiang, Peiyu Pu, Chuanlu Jiang, Chunsheng Kang.   

Abstract

A previous study showed that miR-221/222 can regulate cell apoptosis. p53 is a well known tumor suppressor which can influence the chemosensitivity of glioma cells. However, the effect of miR-221/222 in gliomas with different p53 status is unknown. Here, we demostrate that knockdown of miR-221/222 increases apoptosis in human gliomas of different p53 types (U251 cells, p53 mutant-type; LN308 cells, p53 null-type; and U87 cells, p53 wild-type). Furthermore, the effect of miR-221/22 caused no change of p53 expression in the glioma cells studied. In addition, when a specific siRNA against p53 was employed in U87 cells, no attenuation of apoptosis was found after knockdown of miR-221/222. Importantly, we found that As-miR-221/222-treated cells increased expression of Bax, cytochrome c, Apaf-1 and cleaved-caspase-3. Our results showed that low expression of miR-221/222 sensitized glioma cells to temozolomide (TMZ); in addition, ectopic expression of PUMA by pcDNA-PUMA had a similar effect. Taken together, our study indicates that downregulated miR-221/222 can sensitize glioma cells to TMZ by regulating apoptosis independently of p53 status.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22075712     DOI: 10.3892/or.2011.1535

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  42 in total

Review 1.  Deregulation of microRNA expression in thyroid neoplasias.

Authors:  Pierlorenzo Pallante; Sabrina Battista; Giovanna Maria Pierantoni; Alfredo Fusco
Journal:  Nat Rev Endocrinol       Date:  2013-11-19       Impact factor: 43.330

2.  Plasma miR-221/222 Family as Novel Descriptive and Prognostic Biomarkers for Glioma.

Authors:  Rui Zhang; Bo Pang; Tao Xin; Hua Guo; Yi Xing; Shangchen Xu; Bin Feng; Bin Liu; Qi Pang
Journal:  Mol Neurobiol       Date:  2015-01-31       Impact factor: 5.590

3.  MiR-16 modulate temozolomide resistance by regulating BCL-2 in human glioma cells.

Authors:  Jing Han; Qianxue Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

Review 4.  Extracellular Vesicles and MicroRNAs: Their Role in Tumorigenicity and Therapy for Brain Tumors.

Authors:  Agnieszka Bronisz; Jakub Godlewski; E Antonio Chiocca
Journal:  Cell Mol Neurobiol       Date:  2016-03-17       Impact factor: 5.046

5.  Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma.

Authors:  Jian-Kai Yang; Ji-Peng Yang; Jing Tong; Shi-Yuan Jing; Bo Fan; Feng Wang; Guo-Zhu Sun; Bao-Hua Jiao
Journal:  J Neurooncol       Date:  2016-11-11       Impact factor: 4.130

6.  Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature.

Authors:  Josie Hayes; Helene Thygesen; Charlotte Tumilson; Alastair Droop; Marjorie Boissinot; Thomas A Hughes; David Westhead; Jane E Alder; Lisa Shaw; Susan C Short; Sean E Lawler
Journal:  Mol Oncol       Date:  2014-11-28       Impact factor: 6.603

7.  Uptake by human glioma cell lines and biological effects of a peptide-nucleic acids targeting miR-221.

Authors:  Eleonora Brognara; Enrica Fabbri; Elena Bazzoli; Giulia Montagner; Claudio Ghimenton; Albino Eccher; Cinzia Cantù; Alex Manicardi; Nicoletta Bianchi; Alessia Finotti; Giulia Breveglieri; Monica Borgatti; Roberto Corradini; Valentino Bezzerri; Giulio Cabrini; Roberto Gambari
Journal:  J Neurooncol       Date:  2014-03-05       Impact factor: 4.130

Review 8.  MicroRNAs involved in chemo- and radioresistance of high-grade gliomas.

Authors:  Andrej Besse; Jiri Sana; Pavel Fadrus; Ondrej Slaby
Journal:  Tumour Biol       Date:  2013-04-09

9.  A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells.

Authors:  Annamaria Gullà; Maria Teresa Di Martino; Maria Eugenia Gallo Cantafio; Eugenio Morelli; Nicola Amodio; Cirino Botta; Maria Rita Pitari; Santo Giovanni Lio; Domenico Britti; Maria Angelica Stamato; Teru Hideshima; Nikhil C Munshi; Kenneth C Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2015-11-02       Impact factor: 12.531

10.  Low-Dose DMC Significantly Enhances the Effect of TMZ on Glioma Cells by Targeting Multiple Signaling Pathways Both In Vivo and In Vitro.

Authors:  Lei Shi; Guan Sun
Journal:  Neuromolecular Med       Date:  2015-10-12       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.